Order Article Reprints

Katopodi T, Petanidis S, Anestakis D, Charalampidis C, Chatziprodromidou I, Floros G, Eskitzis P, Zarogoulidis P, Koulouris C, Sevva C, et al. Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery. Pharmaceutics. 2023; 15(10):2458. https://doi.org/10.3390/pharmaceutics15102458

Katopodi, Theodora, Savvas Petanidis, Doxakis Anestakis, Charalampos Charalampidis, Ioanna Chatziprodromidou, George Floros, Panagiotis Eskitzis, Paul Zarogoulidis, Charilaos Koulouris, Christina Sevva, and et al. 2023. "Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery" Pharmaceutics 15, no. 10: 2458. https://doi.org/10.3390/pharmaceutics15102458

Katopodi, T., Petanidis, S., Anestakis, D., Charalampidis, C., Chatziprodromidou, I., Floros, G., Eskitzis, P., Zarogoulidis, P., Koulouris, C., Sevva, C., Papadopoulos, K., Dagher, M., Varsamis, N., Theodorou, V., Mystakidou, C. M., Katsios, N. I., Farmakis, K., & Kosmidis, C. (2023). Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery. Pharmaceutics, 15(10), 2458. https://doi.org/10.3390/pharmaceutics15102458